RUNX3

Across TCGA pan-cancer cohorts, RUNX3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RUNX3 data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RUNX3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RUNX3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where RUNX3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.455	0.797	.004	39	view →
PDAC	DFS	Quartile	II,III,IV	0.918	0.556	.010	31	view →
LUAD	DFS	Quartile	All	0.802	0.385	<.001	19	view →
GBM	OS	Median	All	0.318	0.840	.047	3	view →
LSCC	DFS	Quartile	II,III,IV	0.529	0.917	.035	2	view →
CCRCC	OS	Median	III,IV	0.620	0.991	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RUNX3–HNSC (DFS)

Open the HNSC breakdown →